RE:RE:RE:ETNB jumos on phase 2 b Nash results I know I can be redundant but the root cause of the low valuation is the terrible terrible decision 5 years ago to do a 55 Million $ Convert instead of issuing stock at 11 US per share .The chickens are coming home to roost !!!
Take away the substantial cash on hand at Entb and the market cap (ex cash) would not be anywhere
close to 500 million...
Cash in a Biotech is akin to blood in our veins !!
There is still life in the Company as a result of an uptick in sales which started after the end of the pandemic which lasted over 2 years but there is little room to maneuver...
With regards to Th1902 they have only 2 options imo..Either terminate the program or continue the program with a partner who would assume ALL future expenses
With regards to Nash I believe they are in a better position but the need for a partner is a must
Cash ffom a partnership agreement in Nash would be a fantastic outcome but what are the odds?
There is of course a nuclear option which would be to do a highly dilutive financing to get a big chunk of Marathon out of the picture
scarlet1967 wrote: Phase 2 NASH company and that's mostly all this company is about, market cap $570m, as of December 2022 had $188m cash if they hold the gain 3/4 billion valuation or over half a billion excluding the cash!
https://www.89bio.com/pipeline/
palinc2000 wrote: Over 250 million $ increase in market cap on this news